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Letter of Transmittal 
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To  
Samina Haque 
Lecturer,  
BRAC Business School  
BRAC University  
 
Subject: Submission of Internship Report  
 
Dear Madam, 
  
With due respect, I’m Maeesha Shahla Mridha (10304011), would like to inform you that  
it is a great pleasure for me to submit the internship report under Finance Department  
which is all about on “Financial Ratios Analysis of GlaxoSmithKline 
Bangladesh Limited” as a requirement for BBA program. During preparing the report, I 
acquired lots of knowledge about many unknown facts, problems and prospects of 
Pharmaceuticals and the activities of GlaxoSmithKline Bangladesh Limited. I have put 
my best effort to make this report a successful one. It has been joyful & enlightening 
experience for me to work in the organization & prepare this report. However this has 
been obviously a great source of learning for me to conduct similar types of studies in the 
future.  
 
Therefore, I firmly believe that, this report will be able to meet your approval. I would 
genuinely appreciate to make further corrections where it seems necessary by you. Your 
kind advice will encourage me to conduct more work in future. 
 
 
Sincerely Yours, 
 
_____________________ 
Maeesha Shahla Mridha 
ID: 10304011 
 
 
2 
 
ACKNOWLEDGEMENT 
 
 
At first I want to thank Almighty Allah who enabled me to complete this report. I would 
like to express my sincere gratitude and appreciation to my Faculty Advisor, Ms. Samina 
Haque which would not have been possible for me to complete this report without her 
help, advice and overall supervision. This constant encouragement and supervision 
throughout the period of this study have been greatest inducement for me and directly 
contributed to the accomplishment of the task.  
 
I am also indebted to Mr. Sarwar  Azam Khan(Finance Director) and A.K.M Firoz Alam 
(Director, Human Resources) for allowing me to do my placement at GlaxoSmithKline 
Bangladesh Limited. I would also like to thank my supervisor at GlaxoSmithKline 
Bangladesh Limited Mr. Prasenjit Dev (Internal Audit Manager), Mr. Nizam Uddin 
(Company Deputy Secretary), Mr. Probal Raha (Secretarial Manager), Ms. Syeda 
Mehruna Mahbub (Secretarial Executive) along with others who have been supportive 
through my internship. Equally, I would also like to thank the authority of BRAC 
University Bangladesh for their kind cooperation. 
 
 
 
 
 
 
 
 
 
 
 
3 
 
Executive Summary 
 
This internship report is prepared on Financial Ratios Analysis of GlaxoSmithKline 
Bangladesh, the report includes the process of reviewing and evaluating the company’s 
financial statements because without this the ratio analysis cannot be done. Ratio analysis 
mainly calculates the statistical relationships between data. The ratio analysis helps an 
organization to understand that on the last fiscal year, how their performance and it was 
also helps them to take decisions in future.  
I have selected this topic by consulting with my academic supervisor. The beginning part 
of my report contains the brief introduction of the selected company and the objectives, 
scope, methodology and limitations of the study.  
In the second part, I have covered the detailed background of the company such as the 
history, global network, mission & strategy, the organizational structure, market position 
and an overview of its products and operations.  
In the third part, I have shared my internship experience at Secretarial & Legal 
Department of GlaxoSmithKline Bangladesh Ltd. Here I have presented both mine and 
the departmental job responsibilities. In this part, I have also described my observation 
and understanding about the organization. Lastly I have give some recommendation about 
the organization’s overall performance.  
Then starts the main analysis part of my report where I have analyzed 22 ratios of 
consecutive five years. Here I have presented the result and according the result, I have 
interpreted the financial condition of GSK Bangladesh Ltd.  
In the next part, I have discussed my findings about the financial performance of 
GlaxoSmithKline Bangladesh Ltd and based on the findings I have given some 
recommendations that will help GSK to strengthen their financial base more.  
Lastly I have come up with a brief conclusion and then presented appendix and necessary 
references. 
 
 
 
 
 
4 
 
Table of Content 
 
Chapter 1: Introduction  
 
1.1: Introduction…………………………………………………………………...6  
1.2: Objective of the Study………………………………………………………...7  
1.3: Scope…………………………………………………………………………..7  
1.4: Methodology ………………………………………………………………….7  
1.5: Limitations……………………………………………………………………7-8  
 
Chapter 2: Organization Overview  
 
2.1: GSK at a Glance………………………………………………………………9  
2.2: GSK in Time………………………………………………………………….10  
2.3: History………………………………………………………………………..11  
2.4: Global Operation……………………………………………………………..12  
2.5: The GlaxoSmithKline Bangladesh Limited………………………………12-13  
2.6: GSK Bangladesh Facts ………………………………………………………13  
2.7: Mission, Vision, Strategy ……………………………………………….. 14-15  
2.8: Operations in Bangladesh………………………………………………...15-17  
2.9: Organogram…………………………………………………………………...18  
2.10: Functional Department of GSK…………………………………………18-20  
2.11: Product line of GSK BD……………………………………………………..21  
2.12: Market Share Position of GSK……………………………………………...22  
2.13: SWOT Analysis of GSK…………………………………………………….23  
 
 
Chapter 3: Internship Experience  
 
3.1:  Job Description……………………………………………………………24-25  
3.2:  Different aspects of job performance………………………………………...25  
3.3:  Critical Observation & Recommendation……………………………………26 
 
 
 
5 
 
Chapter 4: Project Analysis and Findings  
 
4.0: Ratio Analysis……………………………………………………………….27  
4.1: Current Ratio……………………………………………………………..27-28  
4.2: Fixed Asset Turnover…………………………………………………….28-29  
4.3: Debt to Equity Ratio…………………………………………………………29  
4.4: Gross Profit Margin …………………………………………………………30  
4.5: Return on Asset……………………………………………………………...30  
4.6: Return on Equity……………………………………………………………..31  
4.7: Earning Per Share…………………………………………………………….31  
4.8: Price Earnings Ratio………………………………………………………….32 
4.9: Findings ………………………………………………………………………33  
 
 
 
Chapter 5: Recommendation and Conclusion  
 
5.1:  Recommendation…………………………………………………………….34  
5.2:  Conclusion…………………………………………………………………...35  
5.3: Appendix…………………………………………………………………37-38 
 
 
Chapter 6: References………………………………………………..39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
 
Chapter 1: Introduction 
 
 
1.1 : Introduction 
 
The pharmaceutical industry in Bangladesh is one of the most developed hi-tech sectors 
within the country's economy. After the promulgation of Drug Control Ordinance in 1982, 
the local pharmaceuticals companies of our country get rapid support for growth and 
development of this sector was accelerated however, from then MNC’s are lag behind. 
There are now about 231 companies in this sector and the approximate total market size is 
about Taka 76,500 million per year. Bangladesh Pharmaceutical Industry is now heading 
towards self-sufficiency in meeting the local demand. The industry is the second highest 
contributor to the national exchequer after garments, and it is the largest white-collar 
intensive employment sector of the country. 
GlaxoSmithKline (GSK) is one of the leading multinational companies in the world and 
the sector it covers is mainly the pharmaceutical industry, besides this it also concentrates 
on consumer health care products. Although the business portfolio of GlaxoSmithKline 
covers two major categories of pharmaceuticals and consumer health care but it 
successfully runs both sector. GSK has a strong Research and Development which works 
really hard to give best health facilities to the customers and keeps pace with the rapidly 
changing health care environment very well.GSK is headquartered in London, United 
Kingdom and the company sells its products in around 70 countries. GSK supplies 
products to 140 global markets and has over 100,000 employees worldwide.GSK has 180 
manufacturing site in 41 countries. Based on published annual reports of the global 
pharmaceuticals companies, GSK has ranked in Sensodyne , Boost, Horlicks, Lucozade, 
Ribena and Gaviscon. GSK has gained leadership in four major therapeutic areas which 
include anti invectives, central nervous system (CNS) and respiratory & gastro- intestinal/ 
metabolic. Moreover, GSK is also gaining leadership in the most significant areas of 
vaccines and it has also an emerging portfolio in a very sensitive segment and that is 
oncology. It is concentrating a lot in making strong quality oncology products. 
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1.2 Objective of the Study 
The primary objective of this report is to get an extensive idea about the Financial 
Analysis  of GSK Bangladesh. Secondary objective is to fulfill my internship requirement. 
 
1.3 Scope of the Study 
Defining the scope of the study is a broad aspect to be described. Definitely Secretarial & 
Finance department helped me a lot to prepare the report but still there were some 
limitations as confidentiality is strictly maintained in GSK BD Ltd. 
 
1.4 Methodology of the Study 
Data Collection  
In order to complete the study, two types of data have been used-  
¾ Primary Data  
¾ Secondary Data  
 
Primary Data was collected through organizing an interview with the Finance Manager & 
Secretarial Executive.  
Secondary Data was collected mainly through the website of GlaxoSmithKline 
Bangladesh Limited. Besides these, I also studied some published reports and 
organizational documents. 
 
1.5 Limitations of the Study 
Their security concern about revealing the information was one of the biggest challenges for me. 
For ensuring confidentiality GSK authority was unwilling to share some information which was 
really needed to prepare the report. Their official website also contains a limited amount of 
information required for making a report; I mainly covered the information from annual reports  
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and through the primary sources of data. Then the time duration for preparing the report was not 
enough. Lastly, due to the work load I also got limited time to prepare the report. 
As the internship was first practical experience for me, so it was possible for me to understand the 
whole and actual financial performance of GSK. Based on the annual reports data I have used my 
understanding about finance to find out the ratios and interpret the situation. In spite of having 
much difficulties and limitations, I have given my best effort to accomplish the report 
successfully. 
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Chapter 2 : Organizational Overview 
 
GlaxoSmithKline (GSK) is one of the world’s leading research based pharmaceutical and 
healthcare companies which is committed to improve the standard of human life through 
enabling them to do more, feel better and live longer. Activities of GSK throughout the 
whole world are presented below: 
 
2.1 GSK at a Glance 
 GSK’s mission is to improve the quality of human life by enabling people to do more, 
feel better and live longer 
 GSK is a research-based pharmaceutical company. 
 GSK is committed to tackling the three "priority" diseases identified by the World 
Health Organization: HIV/AIDS, tuberculosis and malaria 
 GSK’s business employs around 99,000 people in over 100 countries 
 GSK makes almost four billion packs of medicines and healthcare products every year 
 In November 2009, GSK launched ViiV Healthcare, a global specialist HIV company 
established by GlaxoSmithKline and Pfizer to deliver advances in treatment and care 
for people living with HIV. 
 Many of the consumer brands are household names: Ribena, Horlicks, Lucozade, 
Aquafresh, Sensodyne, Panadol, Tums, and Zovirax 
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2.2  GlaxoSmithKline in Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In One Hour: Spends more than US $ 450,000 to find new 
products and also donates more than US $ 148 million in cash 
and products to communities around the world.
In One Minute: Over than 1,100 prescriptions are written for 
GlaxoSmithKline. 
In One Day: Over than 200 million people around the world use 
a GSK toothbrush or toothpaste. 
 
In One Second: Over than 30 doses of vaccines are distributed 
by GSK. 
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2.3  History of GlaxoSmithKline 
  
In 1873 
The company was oriented as Joseph Nathan & Company in New Zealand with the 
founding of a small export-import company. It started its operation as a processing unit of 
abundant fresh milk of New Zealand. The only product it was producing Glaxo Baby 
Food. 
  
In 1875  
It started to export baby food to UK Alec Nathan, son of Joseph Nathan, coined the name 
“Glaxo” from “Glactose”. 
  
In 1924  
Joseph Nathan & Company entered the pharmaceutical industry with the manufacture of 
Ostelin, the first Vitamin D preparation. The importance of the pharmaceutical market 
was soon realized. 
  
In 1935  
Glaxo Laboratories Limited was founded with its headquarters at Greenford, Middlesex 
and London for the production and marketing of foods and pharmaceuticals. 
  
In 1947  
After the 2
nd 
world war, Glaxo developed rapidly. Glaxo Laboratories Limited absorbed 
its parent Joseph Nathan & Company, and became a public company.  
 
In 1963  
Edinburgh Pharmaceutical Industries Limited, which owned Duncan, Flock hart and 
Company Limited and MAC Far lane Smith Limited, joined Glaxo. 
 
In 1995  
Glaxo acquired 100% share, of Wellcome PLC on May 01, 1995 and formed Glaxo 
Welcome PLC. 
  
In 1998 
Glaxo Wellcome achieved a number of regulatory milestones for several of its key 
projects, such as ZEFFIX for the treatment of influenza.  
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In 2000 
Glaxo Wellcome and SmithKline Beecham merged to form GlaxoSmithKline; a 
worldwide research based pharmaceutical company. 
2.4  Global Operation 
 
 
 
 
  
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GSK World Wide
Europe USA International Region 
Middle East 
Latin America 
Japan 
China 
Canada 
Sub-Saharan Africa 
Asia Pacific 
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2.5  The GlaxoSmithKline Bangladesh Limited 
 
GlaxoSmithKline Bangladesh Limited carries with it an enviable image and reputation for 
the past 6 decades. GSK Bangladesh as a subsidiary of GlaxoSmithKline plc- one of the 
world’s leading research based pharmaceutical and healthcare companies continues to be 
committed to improve the quality of human life by enabling people do more, feel better 
and live longer. The organization’s principle activities include secondary manufacturing 
of pharmaceutical products and marketing of vaccines, pharmaceutical healthcare 
products and healthcare drinks.  
GSK started its operation in Bangladesh in 1949 and then it was known by its corporate 
entity “Glaxo”. In Bangladesh, Glaxo then mainly used to work as an importer of Glaxo 
Group. Here it started operation in Chittagong. Gradually it became manufacturer from 
importer and in 1967 it settled its factory in Chittagong. This site is still measured as one 
of the Centers of brilliance in manufacturing and supply Chain network of GSK Ltd.  
The global corporate mergers and acquisitions have seen the evolution of the company’s 
identity in the last 6 decades. Keeping similarity with the corporate entity, the business 
unit of GSK in Bangladesh also changed its name to Glaxo Welcome Bangladesh from 
Glaxo because of the Burroughs Welcome acquisition in 1995. Again in 2002 it changed 
its identity to GlaxoSmithKline Bangladesh Ltd because of the merger with 
SmithKlineBeecham.  
The mega merger of the company enables it to deliver cutting edge advancements in 
health care solutions. The rentless commitment, setting of ethical standards and quality 
backed leading edge technology of the company has built a strong relationship between 
stakeholders and GSK Bangladesh. With the ever committed 680 numbers of total 
employees all over the country GSK Bangladesh, which now comprises of both Pharma 
and Consumer, continually strive to meet the GlaxoSmithKline mission.   
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2.6   GSK Bangladesh Facts   
• One of the pioneering pharmaceutical companies in Bangladesh, GlaxoSmithKline 
started its operation in 1967.  
• GSK is a secondary producer, principally packaging and distributing advanced 
pharmaceuticals products produced by its parent company. Consequently, local 
value added is low.  
• In certain novelty products such as asthma and dermatology, GSK enjoys a clear 
advantage because of its parent’s excellent research efforts and product 
development. However, a significant part of the GSK’s pharma portfolio comprises 
of price-controlled “essential products”. So, GSK Bangladesh does not enjoy price 
advantage for such products.  
• Local pharma companies of Bangladesh take advantage of liberal patent regime for 
least developed countries (LDCs), sanctioned by the WTO, which shall remain in 
place till 2016. They produce copies of patented products for the local market. As 
the subsidiary of a global company, GSK does not take advantage of this liberal 
patent regime and does not produce copy drugs. 
• Although GSK has trailed the overall industry in sales growth before a few years at 
a stretch due to the dominance of local manufacturers, they have managed to 
recover from that with large growth in the last couple of years. However it appears 
that GSK is trying to make up for the lack of sales growth through its consumer 
products business which brought in almost half of the total revenue in 2009.  
• The reliance on consumer products may hurt the company’s profitability in future. 
The health drink market is fairly competitive and is often supplied by non-pharma 
food companies whose core advantage is better management of retail marketing and 
distribution systems, promotional events and efficient inventory management. 
Interestingly, GSK has outsourced their distribution operation which has boosted 
their profitability.  
• Although they do not have any big expansion plan, they seemingly have improved 
their contract manufacturing revenue dramatically. However it would be interesting 
to see if that is going to be repeated in future.  
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2.7   Mission, Strategic Intent & Spirit of GSK Bangladesh  
 
Mission  
The mission statement of the business- “ Our global quest is to improve the quality of 
human life by enabling people to do more, feel better and live longer”. 
 
Strategic Goal 
Our strategic intent states our business goal – “We want to become the indisputable 
leader in our industry.”  
 
 
 
Strategies: 
• Grow a diversified global company  
• Deliver more products of value  
• Simplify the operating model  
• Individual Empowerment  
• Building Trust  
 
Spirit 
  
“Our company spirit describes how we need to behave if we are to achieve our goal” 
–We undertake our quest with the enthusiasm of entrepreneurs, excited by the constant 
search for.  
 
Values 
  
• Respect for people  
•  Patient Focus  
• Transparency  
• Integrity  
 
Behaviors:  
 
• Flexible Thinking  
• Continuous Improvement  
• Customer Driven  
• Developing People  
• Enable & Drive Change  
• Building Relationships  
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Quality Statement 
  
“Quality is at the heart of everything we do- from the discovery of the molecule 
through product development, manufacture, supply and sale- and vital to all the 
services that support our business performance.” 
 
2.8  Operations in Bangladesh 
 
 
 
 
 
 
GlaxoSmithKline Bangladesh Limited has twelve District Marketing Offices (DMO) 
throughout the country. These are divided in five zones by which GSK’s products are 
sold.  
 
District Marketing Offices: GSK has 12 District Marketing Offices (DMO) in 
Bangladesh. The locations of  DMOs are shown below-  
 
 
Zone DMO 
Dhaka                                                                                      Dhaka, Mymensing  
 
Chittagong                                                                              Chittagong, Maijdee 
 
Comilla                                                                                             Comilla, Sylhet 
 
Bogra                                                                             Bogra, Rajshahi, Rangpur 
 
Khulna            Khulna, Jessore 
Barisal                                                                                                            Barisal 
 
 
 
 
 
Headquarter  
GlaxoSmithKline Bangladesh Limited 
Corporate Office  
House # 2A, Road # 138.  
Gulshan-1.
    Registered Office & Factory  
    Fouzderhat Industrial Area  
    North Kattali, Chittagong.  
    District Marketing Office  
17 
 
Organizational structure of Company  
Top management:  
As per provisions of the Article of Association, Board of Directors holds periodic 
meetings to resolve issue of policies and strategies, recording minutes/decisions for 
implementation by the Executive Management. 
  
Executive Management:  
The Managing Director heads the Executive Management, the Chief Executive Officer 
(CEO) who has been delegated necessary and adequate authority by the Board of 
Directors. The Executive Management operates through further delegations of authority at 
every echelon of the line management. 
 
 
 
Name of Directors  
 
Designation  
 
Numbers of Meetings 
Attended  
 
Mr. Duncan Learmouth  
 
Chairman  
 
1 out of 5 meetings  
 
Mr. M Azizul Huq  
 
Managing Director  
 
5 out of 5 meetings 
Mr. Golam Quddus 
Chowdhury 
Non-Executive and 
Independent  
Director 
4 out of 5 meetings 
Mr. Sarwar Azam Khan Finance Director & 
Company  
Secretary 
5  out of 5 meetings 
Mr. Md. Fakeyuzzaman Non-Executive Director  
 
4  out of 5 meetings 
Mr. Rajib Barua Site Director  
 
5  out of 5 meetings 
Mr. Pawan Sud General Manager  
 
3  out of 5 meetings 
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Human Resources  
HR department is one of the most active departments in GSK. Previously this department 
was known as “Personnel Management” department. The company places great 
emphasis and commitment in developing the human resources as the management body 
believes that only the best people with professional competencies can contribute 
successfully to achieve the organization’s goals. GSK has two HR Division, one is at 
corporate head office and other one is Chittagong factory office. There are four functional 
sub-departments. They are- HR Development, HR Services, HR Administration and 
Industrial Relations. First three sub departments are looked after by corporate head office 
HR division and last one is looked after by Chittagong HR division. There are various 
functions of HR department of GSK. The main activities of this department are given 
below-  
1. Recruiting and training the best pool of employees according to company’s 
requirement  
2. Administering smooth workflow in the organization 
3. Managing demands of the labors in the factory  
4. Allocating annual holidays  
5. Organizing motivational programs for employees  
6. Looking after the wage structures and waivers 
 
At corporate head office six-member HR division takes care of GSK, Bangladesh, LTD. 
The member and their chain of authority are shown in the organogram below-  
Marketing  
The pharmaceutical industry of Bangladesh has limited field for marketing. Yet in an age 
of high competition like todays, firms are heavily spending and effectively practicing 
marketing. The summary of marketing functions is given below-  
1. Designing and implementing sales strategies  
2. Controlling and updating distribution network  
3. Designing and carrying out promotional programs  
4. Providing marketing information services  
5. Carrying out different awareness programs  
6. Controlling international trades  
7. Keeping records of data regarding marketing activities  
8. Building up public communication network  
9. Looking after all the brands and patents  
10. Conducting marketing surveys as needed  
20 
 
Finance  
 
GSK gives proper importance to their finance department The financial statements of 
GSK have been prepared in accordance with Bangladesh Accounting Standards and the 
relevant requirements of the schedule to the Securities and Exchange Rules, 1987 and of 
the companies Act 1994 following the historical cost conversion. The primary tasks of 
finance department are given below-  
1. Controlling the accounts  
2. Completing annual budgets 
3. Allocating all kinds of payments to the staffs and managers  
4. Looking after all the revenue and expenses  
5. Conducting internal audit  
6. Keeping records through IT  
7. Facilitating local production costs  
 
Medical and regulatory affairs  
Medical and Regulatory Department of GSK, Bangladesh is compiled with required 
number of doctors and qualified people. This department is primarily responsible to 
perform tasks like liaison with government for legal issue purpose, communicate with 
doctors, handling advertisements, etc.  
Information Technology  
 
The technical department of GSK is extraordinarily strong. The organization always 
strives for reaching the global standard of applications of information technology. This 
company is one of the very few companies in Bangladesh that use world class 
sophisticated software. 
2.11  Product line of GSK Bangladesh Limited  
 
GlaxoSmithKline operates principally in two industry segments:  
1. Pharmaceuticals:  prescriptions, medicine and vaccines.  
2. Consumer HealthCare:  Over the counter medicines, Oral care and nutritional 
healthcare products. 
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Product overview:  
1. Pharmaceuticals:  
GSK’s board pharmaceuticals product line includes antibiotic, antidepressant, 
gastrointestinal, dermatological, respiration, cancer and cardiovascular medications. GSK 
has a variety of vaccine products, including hepatitis A and B, diphtheria, tetanus, 
whooping cough and influenza.  
 
2. Consumer Healthcare:  
GSK Consumer Health brings oral health care, over the counter medicines and nutritional 
health care products to millions of people. 
 
GlaxoSmithKline Products  Glossary 
 
 
 
Local production 
60 products including 
Berin 
Cytamen 
Kefdrin 
Pentamox 
 
Imported product 
17 products including 
Alkeran 
Seretide 
Zinnat 
 
Vaccines 
17 products including 
Engerix-B 
Fluarix 
Synflorix 
 
 
 
Consumer Healthcare 
9 products including 
Horlicks 
Chocolate Horlicks 
Junior Horlicks 
Mother Horlicks 
Horlicks Lite 
Boost 
Maltova 
Glaxose 
 
 
Figure: GSK Product Glossary (Source: Marketing department GSK, Bangladesh) 
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 2.12:  GSK’S Market Share & Position Comparison 
  
 
 
 
 
 
 
 
 
Companies  
 
 
According to the Year 
2013 
 
 
 
 
Market Share 
 
 
 
 
 
 
 
 
Ranking  
SQUARE  18.78 %  1  
INCEPTA PHARMA  9.21 %  2  
BEXIMCO  8.75 %  3  
OPSONIN PHARMA  5.07 %  4  
RENATA  4.87 %  5  
ESKAYEF  4.80 %  6  
ACME  4.26 %  7  
A.C.I.  4.20 %  8  
ARISTOPHARMA  4.04 %  9  
DRUG 
INTERNATIONAL  
3.63 %  10  
SANOFI AVENTIS  2.53 %  11  
HEALTHCARE 
PHARMA  
1.88 %  12  
ORION PHARMA LTD  1.85 %  13  
NOVO NORDISK  1.84 %  14  
GlaxoSmithKline  1.81 %  15  
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2.13:  GSK BD’s SWOT Analysis 
SWOT is the short form for Strengths, Weaknesses, Opportunities and Threats. It is an 
analytical  construction to help summarize in a quick and concise way the risk and 
opportunities for any Corporation across the value chain.  A good SWOT should consider 
both internal and external factors that influence the organizational operations.  
• Factors pertaining to the internal environment of the company. These are usually 
expressed as Strengths (S) or Weaknesses (W)  
• Factors that pertaining to the external environment of the company. These are 
expressed as Opportunities (O) or Threats (T). 
 
Strength  Weakness  
 
 GSK is considered as world's one of the leading 
pharmaceutical companies because of its 
performance.  
 Efficient, capable and honest workforce  
 GSK has intense demand of their product 
nationally and internationally which helps them to 
inflate their business  
 Considerable financial resources to grow the 
business  
 Proprietary technology and importance patents  
 Ability to take advantage of economies of scale 
 Better product quality relative to rivals  
 Goodwill of the company  
 Follows GMR-Good Manufacturing Practice  
 
 
 Underutilized plant capacity  
 Higher unit cost relative to key competitors  
 Group compliance due to group policy the 
company has to import raw materials form UK 
rather from neighbor countries (other than those 
which are produces locally) resulting in higher cost 
of production. 
  
 Lack of variety in products  
 Low pack size  
 Lack of sufficient promotional effort.  
 GSK has weaker distribution network and sales 
force are relatively low compare to competitors.  
 
Opportunities  Threats 
 
 GSK as a multinational company has 
opportunity for expand its investment and has 
potential growth in Bangladeshi market.  
 
 Expanding the company’s product line to meet 
a broader range of customer reeds.  
 Target and acquire an untapped marketing for 
vaccines  
 Market is significantly large and growing  
 Proper utilization of vaccines may result in 
higher profit.  
 Availability of natural resources is the most 
lucrative opportunity for GSK to work with 
Bangladesh.  
 
 In Bangladesh, GSK can get labors at a very 
cheap cost.  
 High confidence brand name and quality  
 
 
 Adverse shifts in foreign exchange rates and 
trade policies of government  
 Aggressive movement of rivals  
 Slow down in market growth  
 Growing bargaining power of the end 
consumers, thus high priced medicine are 
inconvenient for them  
 Costly new regulatory requirements  
 Competitors lower prices  
 Increasing threats from local competitors.  
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Chapter 3:  Internship Experience 
 
3.1 Job Description 
  
It was really a great opportunity to work as an intern in a well reputed MNC like 
GlaxoSmithKline. I worked there for 3 months under the Internal Audit which is a part of 
the Finance Department and also has a close link with the HR department. My main 
supervisor was Mr. Prasenjit Dev, Internal Audit Manager. On the other hand, I also 
worked with secretarial Department. Working in Secretarial department really gave me 
lots of experience about practical job life and also improved my skills a lot. For this 
reason, I will be always grateful to Md. Nizam Uddin and Mr. Probal Raha because they 
guided me always in the right track thus I can fulfill the tasks in proper manner. In 
addition, I have also worked in the HR department of the company.  
 
Tasks of Secretarial Department:  
 One of the main tasks of Secretarial department is to handle the payment issues of the 
employees. This includes all the employees in both corporate office and Factory site and 
also includes the DMOs.  
 Secretarial department keeps record of all the employees thus any payment issue can 
have the proper evidence which will help both the company and employees in future to 
negotiate properly.  
 Secretarial department keeps contact with banks for different transaction purposes and 
time to time collect the information about deposits and withdrawals about the accounts 
like Pension Fund, Dividend Payment, Provident Fund, Treasury Bills etc.  
 Secretarial department handles the issues like purchasing and encashment of Treasury 
Bills, providing the bonus payments and recording the loan payments given to the 
employees.  
 Secretarial department also handles the allowance issue that is given to the interns and 
that’s why they keep information of all interns thus payment can be made on right time. 
 
Secretarial department continuously keep contacts with the Central Bank, Security and the 
Exchange commission and the Dhaka Stock exchange regarding the audit issues, 
compliance concerns and stock market operations.  
 Secretarial department along with the Finance department significantly participate in 
Annual Report making and publishing and monitoring that it is being completed in the 
exact way and also on due date. Then it is the responsibility of secretarial department to 
monitor that the Annual reports have been distributed to all the shareholders and this 
should be done at least 20days before the AGM.  
 Secretarial department also keeps record of all traveling bills that are made for 
business purposes and also the medical bills of the employees. In the employee list, the 
DMOs are also included. They have the proper right to judge that the expense claim is 
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valid or not and on this issue the secretarial department’s decision is final. They also keep 
records of foreign travel bills.  
 Many medical promotional officers get motorcycles from the company in order to 
carry the products properly. It is the duty of the secretarial department to keep records of 
the motorcycle loans and if any motorcycle is lost or theft then they firstly collect the 
evidence and then decide what to do.  
 Secretarial department keeps the final settlement copies which are basically the details 
of the employees who have left the company. There the payment details of those 
employees are also kept. If any amount is due to the ex-employee it is also recorded and if 
the company has any receivable from the employee then that is also recorded. Secretarial 
Department also keeps the pensioner lists and clears the payments to the pensioner or the 
nominees of the pensioner.  
 Secretarial department also monitors that the employee database software which is the 
Vista 3P and the financial record keeping soft wares are working properly or not, if there 
is any problem then they inform the IT department and ensures that the problem is solved 
within the shortest possible time.  
So, in short the Secretarial department has huge responsibilities and it has to be updated 
with the HR, Communication and the IT department. At the same time, it needs to handle 
the financial and legal issues. Not only it monitors all types of employee payments but 
also needs to monitor company’s different types of bank accounts and legal matters. 
  
3.2  Different Aspects of Job Performance 
  
As I was a part of the Secretarial department, so I had the opportunity to assist my 
supervisor and the Secretarial Executive in different types of tasks.  
One of the main tasks of mine was to check and verify the expense claims of the DMOs. I 
used to follow the company rules while deciding that the expense claim is valid or not.  
Then after checking all the bills I used to input the entries in the system and then also used 
to check that all valid payments have got clearance. If there were any difficulties or 
confusions then I used to inform the Secretarial Executive.  
As, this department has to look after many legal issues so there were a huge files and my 
duty was to categorize and organize all the files and then keeping them in sequence.  
This department needs to contact with different institutions and individuals, in this regard 
sometimes I used to type different sorts of business letters.  
As the department accomplishes the payroll activities, so employees used to visit the 
department for payment purposes and in absence of supervisors, I used to attend them, 
then used to convey their messages and claims to my supervisors.  
Then I used to assist the secretarial executive in checking the balance amount of different 
accounts that has been inputted in the system. 
In my last month, one most crucial task was according to the shareholder’s addresses, 
serially putting the annual reports in envelopes and then keeping records that how much 
annual reports have been sent to the shareholders and how much is remaining.  
I also have worked with the Finance department and HR department; there I used to 
calculate the bills and creating newly joined employee files respectively.  
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Besides these I had also done some other major and minor tasks. In short, I used to spend 
a very busy schedule in GSK but it was full of fun and it also helped me a lot to know the 
core official jobs. The Secretarial department taught me to be punctual, sincere, honest, 
active, efficient and most importantly it taught me how to communicate in the corporate 
world. For enhancing these abilities in me and for providing me such a sophisticated 
environment, I will be ever grateful to GSK and specially the Secretarial department.  
 
3.3 Critical Observation & Recommendation: 
  
Within the 3months’ experience in GSK, I have found that the organization is very 
organized at accomplishing the tasks, it is very much focused at doing fair business and 
the corporate environment is really safe and friendly. GSK Bangladesh truly follows the 
code of conducts which established by its parent company. All the employees here try to 
maintain integrity in their every tasks. All the departments are here properly co-ordinated 
which fosters the organizational performance a lot. Here the importance of human asset is 
truly realized and all the employees are believed as the heart of the organization and that’s 
why the employees work here with true motivation and sincerity. As I was the part of 
Secretarial department which is a section of Finance department, I have found that 
employees of these two departments are very much knowledgeable and skilled and very 
efficiently they plan and implement the financial strategies. They are also very much 
aware about utilizing the resources and not to waste the assets of the organization 
unnecessarily.  
I have observed and felt that GSK Bangladesh is doing excellent job, one thing that 
appeared surprising to me is in spite being so efficient at operations and having so much 
qualified products, GSK Bangladesh is in 15
th 
position. Market leaders are the local firms, 
the reason behind this is the government concern to promote the local pharmaceuticals. 
So, GSK should take strong initiatives thus they can improve their rank and can lag 
behind the competitors. On the other hand, most of the consumer health care products are 
doing so well, especially the health drinks and the glucose powder.  
So, my recommendations are:  
GSK should concentrate more on promotional activities and making people more aware 
about their company profile and products thus a strong brand image can be established.  
• Like the Consumer Healthcare products, the pharmaceuticals products should be 
engaged in famous public events.  
• They should be more concerned to reduce the production cost of the pharma 
products thus they can compete with the local products more successfully.  
• GSK should introduce their pharma products more to the public and should inform 
the people that it is the same company which makes horlicks and boost. 
•  GSK should be very careful in maintaining the copyrights of their products as they 
are in alliance with some local firms like Mutual food and Zuellig Pharma. 
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Chapter 4: Project Analysis and Findings 
 
4.0  Ratio Analysis 
  
Ratio Analysis is done to measure the financial performance of the company and to 
understand that in which track the company is going in the future. So, it is basically one 
technique of assessing the company’s financial performance.  
In ratio analysis, financial items of a particular year are compared. Here relationships 
between the financial items are examined. So, by doing ratio analysis we can judge the 
various financial aspects of a firm. Then when we compare one year’s ratios with another 
then we come to know that how much progress was made during the compared period. 
The ratio analysis is very important to investors, creditors and financial analysts as it helps 
in decision making.  
In order to evaluate GSK’s financial performance, I have also selected ratio analysis as the 
analyzing tool.  
  
Ratios Analysis of GSK 
 
4.1: Current Ratio 
 
Current ratio is an efficient tool to measure that the organization is capable in meeting up 
its short term debts or not. Current ratio basically assesses a firm’s liquidity because, if a 
firm is enough liquid and it has enough resources then it can pay back the all debts that 
need to cover during 12 months.  
 
Formula: Current Assets ⁄ Current Liabilities 
 
Higher current ratio definitely indicates that the firm is highly liquid and able enough to 
meet the demands of the creditors. Satisfactory current ratio actually varies from industry 
to industry but in general, if the current ratio lies between 1.5 and 3 then it indicates that 
the business is healthy. If the current ratio is below 1then it means that the current 
liabilities are higher than the current asset, so the firm can face many difficulties while 
paying back short term debts. On the other hand if the current ratio is too high then it 
indicates that the firm is not efficient to utilize its short term financing facilities. It may 
also indicate that the firm has problem in working capital management.  
Low current ratios normally indicate that the firm is in trouble to meet current obligation 
but not necessarily always a low current ratio indicates a huge problem. Firms which have 
not much currents assets but have a strong long term plans and prospects, they definitely 
can sort out ways to tackle this problem. There are many firms who have a current ratio 
under 1 but they are surviving quite well. So, low current ratio does not always mean that 
the firm is at an alarming stage or very near to be bankrupt but of course it is better to 
maintain a standard current ratio in order to ensure fewer risks.  
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From the perspective of short term creditors, a high current ratio is appreciable because it 
means that the company is eager to pay back current debts within 12 months. A high 
current ratio also indicates that the firm is much efficient to convert its goods into cash 
quickly.  
In short, current ratio should be compared within the same industry as the benchmark ratio 
varies from industry to industry. 
 
Current Ratio of GSK: 
 
Year 2009 2010 2011 2012 2013 
Current 
Ratio 
3.11 2.59 2.01 1.79 1.69 
 
Over the five years, GSK had highest current ratio in 2009 and the amount was 3.11. This 
quite high figure indicates that GSK did not utilize its current assets to raise funds for the 
business growth. Then in 2010 it was quite low than 2009 and the amount was 2.59 which 
is still high but the decrease in the ratio indicates that on that year GSK tried to make 
proper use of the current assets. Then in 2011 it was again decreased and it continued by 
decreasing in 2012 and 2013 that means it was not in proper control. Most satisfactory 
point is that, GSK Bangladesh had no lower current ratios over these five years which is 
an indication that GSK has enough liquid assets or cash by which they can save their 
business from big troubles. In 2013, it is also in the standard level which indicates well 
performance. 
 
4.2:  Fixed Asset Turnover:  
 
It is the ratio where sales are compared with the fixed assets of the firm. The ratio actually 
clarifies that the firm is capable enough to use its fixed assets to earn revenues or not. In 
fixed asset turn over, normally investments on property, plant and equipment are counted 
and the depreciations of these are subtracted. A high fixed asset turnover is always 
appreciable as it signals towards the firm’s high productivity. Higher fixed asset turnover 
means the firm is utilizing its fixed assets and generating revenues from these. On the 
other hand, low fixed asset is the signal that the firm is not productive and the firm fails to 
generate sales revenue by utilizing the fixed assets.  
There is neither standard guideline nor a best level for fixed asset turnover, so the 
evaluation and comparison can be done by calculating fixed asset turnovers of past years 
of a particular organization. As there is no average figure, so progress of the firm can also 
be accessed through comparing fixed asset turnovers of different firms of the same 
industry. High fixed asset turnover means that less money is allocated to the fixed asset 
portion, where as too low fixed asset turnover means that additional fixed asset investment 
has been made which is unnecessary. So, the investment in fixed assets should be in the 
right amount, neither more nor less and most importantly it should be monitored that the 
assets are being utilizing properly thus they can contribute to high revenues. 
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Fixed Asset Turnover = Net Sales ⁄ Fixed Asset (Plant, Property, Equipment) 
 
 
Year 2009 2010 2011 2012 2013 
Fixed Asset 
Turnover 
Ratio 
8.67 10.41 9.85 11.16 12.62 
 
GSK had an increasing fixed asset turnover from the year 2009 to 2013. Although there 
was a little bit falls in the fixed asset turnover in 2011 but the difference from 2010 is only 
.02 so this is not any significant issue. If we compare from 2009 then will find it started 
from 8.23 and two gradual increases, it reached at 11.16 in 2012 and12.62  in 2013. So the 
progress is quite high. This high trend actually indicates that GSK has become more 
efficient is asset utilization over these six years. 
 
4.3:  Debt to Equity Ratio 
 
The debt to equity ratio is the best way to measure the financial leverage of any firm; it is 
one of the most important ratios of any firm. Higher the ratio, higher the debt amount of 
the firm, therefore higher financial leverage.  
If the ratio is lower, the leverage of the firm is also lower. It presents the parentage of a 
company’s asset that is financed by debt versus equity. It is a widespread quantity of the 
long term capability of a firm’s business and along with current ratio, a measure of its 
liquidity, or its ability to cover its expenses. So, it often takes only long term debts instead 
of total liabilities.  
Sometimes, it happens that higher debt leads the firm to gain higher debt as cost of debt is 
lower than the cost of equity but it is not good for the firm to always apply this technique 
because if the firm fails to meet up the obligations of debts ten the firm can reach even in 
the stage of the bankruptcy. So, the firms should be much analytical and attentive when to 
take higher debts. Higher debt can lead to both higher gain and risk, so firms should be 
very careful while taking financial leverage.  
 
Formula: Total Debt / Shareholder’s Equity 
 
Debt to Equity Ratio of GSK: 
 
Year 2009 2010 2011 2012 2013 
Debt to 
Equity 
Ratio 
0.46 0.60 0.83 1.06 1.16 
 
The debt to equity ratio had an increasing number over the five years which indicates that 
GSK is taking more financial leverage and also depending on more debts. In 2012 and 
2013 the ratio were too high, it was 1.06 and 1.16 respectively which might lead the firm 
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towards huge risk. Yes, higher debt can increase the earnings a lot but it is only possible 
when the cost of debt is affordable by the company. 
 
 
 
4.4:  Gross Profit Margin Ratio 
 
Profitability depends on a large number of policies and managerial decisions of a firm. All 
the effects of liquidity, asset and debt management on the income s judged through the 
profitability ratios. Gross profit Margin, Profit Margin, Return on Assets and Return on 
Equity are the mostly used profitability ratios.  
The relationship of sales and cost of goods sold is assessed through gross profit margin. 
High ratio indicates a secure position for the company. Low profit margin signals towards 
less safe position because it means that sales are diminishing, therefore generating low 
revenues. It is also a great tool of identifying pricing strategy and cost control. It helps to 
cut cost by presenting that cost is relatively low or high than the revenues. So, from the 
low profit margin we actually get the idea that I which way we need to control our costs.  
 
Formula:  Gross Profit Margin = Gross Profit / Sales 
 
Gross Profit Margin of GSK: 
 
Year 2009 2010 2011 2012 2013 
Gross Profit 
Margin 
Ratio 
31.23 34.20 28.48 28.61 32.67 
 
Over the first two years, the gross profit margin has increased gradually by slight amount 
but in 2011 there was a downfall and in 2012 it increased by only in a little point. In 2011 
the sales were higher than previous four  years but the costs associated with the sales were 
also too high, for this reason the margin was low. From this result, GSK tried to control 
the cost and as a result the situation was little better in 2012 than that of 2011. On the 
other hand, in 2013 the ratio became higher again that means they tried to reduce the cost 
than before. One positive thing we can notice that the performance of GSK was quite 
stable in terms of gross profit margin which means throughout these years the GSK 
Bangladesh Ltd faced less fluctuations, therefore had much secured position. 
 
4.5:  Return on Assets (ROA) 
 
ROA is the measurement tool by which we can know that a firm is how much profitable 
in comparison with its total assets. So, it measures that the firm how efficiently uses its 
assets to generate profits. This is also known as Return On Investment (ROI) as it tells 
that a firm how effectively transforms its investments on profits. It is often expressed in 
percentage. Higher ROA is always desired as it indicates that higher profit has been made 
through fewer investments.  
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Formula:  ROA=Net Income/Total Assets  
 
ROA of GSK: 
 
Year 2009 2010 2011 2012 2013 
Return on 
Assets 
.19 .19 .11 .08 .14 
 
In 2009 the ROA was 19% and then it was same in 2010 which indicates successful 
management policies of GSK. Then in 2011 and 2012 but this year the percentage of 
downfall is lower than 2011. After that it increased again in 2013 which is satisfactory.  
 
4.6:  Return on Equity (ROE) 
 
Return on Equity is the ratio of net income to total shareholder’s equity. It measures that 
the firm how much earns from the shareholders’ equity. It also shows the firm’s efficiency 
at generating profits from every dollar of equity capital. Increasing ROE indicates 
improved performance. In accounting sense, ROE is the true bottom line of performance 
measurement. 
  
Formula:  ROE= Net Income/Total Equity Capital 
 
ROE of GSK: 
 
Year 2009 2010 2011 2012 2013 
Return on 
Equity 
27.82% 29.70% 19.83% 16.42% 29.51% 
 
From the above we can see that, in 2009 and 2010 there was an improvement in ROE, 
over these 2 years it increased by almost 2% but in 2011 it decreased by 19.83% which is 
not a good indication. In 2012 the downfall continued which indicates that GSK’s 
management efficiency is lower than previous years and it is earning less profit from the 
equity capital. After that there is a huge progress in 2013 which is really satisfactory for 
the condition of GSK. 
 
 
4.7:  Earning Per Share 
 
Earning per share or EPS expresses the earned profit against per share. It is considered as 
an important tool while measuring a stock’s performance. Investors often judge the firms 
with the EPS and always prefer a high EPS. However, always high EPS does not mean 
that the firm is doing well because the Net income can be manipulated and for this reason 
EPS can be overestimated. Often firms do these in order to attract the public. So, relying 
only on EPS is never a wise decision. Another important point is, same EPS of two firms 
do not indicate that the firms are equally strong; here we need to judge that which firm has 
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earned same EPS by less investment. The firm which has done so is in better position and 
more efficient. 
 
Formula: Net Income/ Number of Common Stock Outstanding 
 
EPS of GSK: 
 
  
Year 2009 2010 2011 2012 2013 
Earning Per 
Share 
26.88 34.05 23.42 20.25 45.35 
 
In the year 2009, the EPS was low but in 2010 it increased a lot which indicates that 
earnings against each share were high on those years. In 2011 the EPS dropped by 10.63tk 
and in 2012 it again dropped by 3.17 tk. So, GSK should take initiative to increase the 
EPS otherwise it may create confusion about the financial condition to the general public. 
But in 2013 they increased their EPS in a huge amount which is really good for the 
earnings from their share. 
 
4.8: Price Earning Ratio (P/E) 
 
This is the ratio of market value to EPS. Through this ratio, the recent trading price of the 
firm is compared with its EPS.  
The P/E ratio actually represents the expectation of investors about the firm. Higher P/E 
means that investors have high expectations about the firm’s future growth and that’s why 
they are interested to invest. 
The P/E ratio has also another meaning, sometimes it also indicates that how 
much the investors are willing to pay for per dollar of earnings. So, in this case 
it is referred as multiple. The average P/E ratio is 20-25 times. Comparing P/E 
ratio within firms of same industry gives the idea that which firm is performing 
well. 
  
Formula:  P/E ratio= Market Price/EPS 
 
 
Year 2009 2010 2011 2012 2013 
Price 
Earning 
Ratio 
26.98 33.17 28.37 28.15 21.07 
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Over the last five years, the P/E ratio of GSK was quite good upto 2010 which means that 
investors have great interest on GSK, this is because GSK is a well reputed multinational 
firm and has a unique brand image. In 2010 the ratio was higher than the other four years 
which means it was overvalued and in 2011 it was lower than the previous years and 
continued in a decreasing form in the rest of the years but higher than the standard figure. 
So, from 2009 to 2012 it is quite stable but it was the lowest in 2013but still higher than 
standard which indicates that people have positive opinion about the stocks of GSK. 
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4.9:  Findings 
  
The factors I have identified through my analysis are:  
 
• GSK has a very little amount of  long term debt  
• GSK earns a significant amount every year, its current ratio and turnover ratios are 
satisfactory which indicates that GSK is performing well.  
• GSK has enormous production capacity but it is not fully utilizing this opportunity 
and it is not producing cheaper products than the competitors.  
• GSK has a policy, that the MPOs cannot pursue the doctors to recommend its drugs 
and as a result it is lagging behind in this sector.  
• GSK’s distribution channel is not that much strong compare to the local firms. 
•  GSK is not undercapitalized which means GSK does not only depend on borrowed 
capital and the creditors. So its owned capital is able to meet up the operational 
costs. So, obviously GSK is financially solvent. 
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Chapter 5: Recommendation and Conclusion 
 
5.1: Recommendation  
 
 
• Although GSK is maintaining a fair current ratio, but from 2009 to 2012 it is 
gradually decreasing which is an indication that current liabilities are increasing. 
So, GSK must concentrate on this issue and should be careful to control the debts.  
 
• There is an increase of  debt to equity ratio, again it is pointing out that debts are 
increasing. Although higher debts can give financial leverage but there is also a risk 
of meeting up the debt obligations. So, GSK should realize that higher debts can 
lead it to higher risk. From now it should be little conservative in case of taking 
debts.  
 
 
• Most of the profitability ratios are decreasing. So, it means the growth is lowering 
day by day. In this case GSK must needs to think that how more profit can be 
achieved and needs to find ways to capture the significant portion of the market 
thus profit level goes up.  
 
•  In 2011 the sales growth was much higher than 2010 and in 2012 this trend was 
maintained. Although it’s a very positive indication but GSK should not forget that 
it can increase the market share more. So, in this regard it should increase the 
promotional activities to capture the consumer mind more.  
 
 
• Market coverage can be expanded through reaching the every corner of the country. 
GSK needs to adopt more aggressive strategy in order to beat the competitors. 
  
•  GSK needs to change its policy of not pursuing the doctors to prescribe its drugs; 
otherwise it will not be able to cope up with the local giants. 
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5.2:  Conclusion 
 
 
Financial ratios analysis is a part of financial statement analysis and through this we can 
have knowledge about the company’s past and present performance. Most importantly it 
gives us an idea that what can be the company’s performance in the future. Ratio analysis 
involves the calculation of statistical relationship between data and it is a very popular 
technique of financial statement analysis. Throughout my analysis, I came to know about 
the financial strength, operational efficacy and management efficacy of GSK. I have 
realized that GSK is performing well, it is financially solvents but there some threats 
which are increasing recently. If the risks or threats can behandled properly then definitely 
GSK can survive successfully as like the previous years. 
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5.3: Appendix 
 
   2009 2010 2011 2012 2013
1. Current Ratio                
                 
Current Assets  3,122,101 37,31,643 21,65,430  2,500,449 3,411,251
Current Liabilities  1,003,891 14,40,789 10,77,330  1,433,857 2,020,248
                 
Current Assets/Current Liabilities  3.11009999 2.58999964 2.00999693 1.743862184 1.688530814
                 
   2009 2010 2011 2012 2013
2. Fixed Asset Turnover                
                 
Net Sales  3,023,672 3,632,095 4,735,121 5,553,812 6,774,872
Fixed Asset  348,815 348,815 480,662 497,830 536,861
                 
Net Sales/Fixed Asset  8.66841162 10.41266861 9.8512489 11.15604122 12.61941545
                 
   2009 2010 2011 2012 2013
3. Debt to Equity Ratio                
              
Total Debt  2719808 891336 1180500 1,577,658 2,146,513
Shareholder's Equity  5,912,626 1,485,560 1,422,290 1,381,151 1,851,112
                 
Total Debt/Shareholder's Equity  0.46 0.6 0.83 1.142277709 1.159580296
                 
   2009 2010 2011 2012 2013
4.Gross Profit Margin Ratio                
                 
Gross Profit  9,44,292 1,242,176 1,348,562 1,588,912 2,213,089
Sales  3,023,672 3,632,095 4,735,121 5,553,812 6,774,872
                 
Gross Profit/Sales  0.31234047 0.342034206 0.28482133 0.286093948 0.326661375
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   2009 2010 2011 2012 2013
5. Return on Assets                
                 
Net Income  323,787 410,177 282,068 243,967 546,249
Total Assets  1,253,942 1,488,884 1,567,268 3,063,218 3,997,625
                 
Net Income/Total Assets  0.19 0.19 0.11 0.079644021 0.136643382
                 
   2009 2010 2011 2012 2013
6. Return on Equity                
                 
Net Income  323,787 410,177 282,068 243,967 546,249
Total Equity  1,163,718 1,381,151 1,422,290 1,485,560 1,851,112
                 
Net Income/Total Equity  0.27823493 0.29698201 0.19831961 0.164225612 0.295092355
In Percentage  27.8234933 29.69820099 19.8319611 16.42256119 29.50923553
   2009 2010 2011 2012 2013
7. Earning Per Share                
                 
Net Income  323,787 410,177 282,068 243,967 546,249
Number of Common Stock 
Outstanding  120,465 120,465 120,465 120,465 120,465
                 
Net Income/Number of Common 
Stock  2.68780973 3.40494749 2.34149338 2.025210642 4.534503798
Outstanding                
   2009 2010 2011 2012 2013
8. Price Earning Ratio                
                 
Market price  725.1 1,129.60 664.5 570 955.7
Earning Per Share  26.88 34.05 23.42 20.25 45.35
                 
Market Price/Earning Per Share  26.9754464 33.17474302 28.3731853 28.14814815 21.0738699
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